Abstract: . . .  hypoglycaemic awareness, despite their importance to people with diabetes , and this issue should be investigated.   Conclusion Diabetes UK feels that all people with diabetes should have choice in the method of their treatment, in consultation with their healthcare professionals. Living with diabetes is about self-management 14 . When people have a choice of therapies and are involved in decision- making, they feel that they are more empowered to take control over their condition. . . .
. . .  apparently unexplained results and hypoglycaemia. needs to be shaken about 20 times to be effectively mixed in pen form. duration of action alters with amount given. can cause nocturnal hypoglycaemia.   New therapies, such as long-acting analogue insulins, provide a greater flexibility and choice of treatment, which may enable individuals living with the condition to take greater control, minimising the long and short term risks of diabetes while maintaining a good quality . . .
. . .  making, they feel that they are more empowered to take control over their condition. This often helps motivate them to take better care of themselves. The views of patients need to be considered as their qualitative experience is valid. Long acting insulin analogues, such as glargine, provide more flexibility and potentially greater accuracy in treatment regimes. This would help many people with diabetes to balance their diabetes control, to minimise the risk both of hypoglycaemia and, potentially, . . .
. . .  they feel that they are more empowered to take control over their condition. This often helps motivate them to take better care of themselves. The views of patients need to be considered as their qualitative experience is valid. Long acting insulin analogues, such as glargine, provide more flexibility and potentially greater accuracy in treatment regimes. This would help many people with diabetes to balance their diabetes control, to minimise the risk both of hypoglycaemia and, potentially, . . .
. . .  a problem. This appears to result in a reduction of nocturnal hypoglycaemia and a more natural insulin profile during the day. Used appropriately with bolus doses of short/rapid acting insulins, this could help achieve better blood glucose control. For some people with diabetes this would minimise the risk of complications, both short and long term. Such insulins also appear to be safe and are already available elsewhere in Europe and the United States.   Insulin glargine has been reported . . .
. . .  to be considered as their qualitative experience is valid. Long acting insulin analogues, such as glargine, provide more flexibility and potentially greater accuracy in treatment regimes. This would help many people with diabetes to balance their diabetes control, to minimise the risk both of hypoglycaemia and, potentially, microvascular complications, whilst working to maintain their own  quality of their life.   We would also like to declare that we have been working on various . . .
--3000,6,250,3454,17015